WARNER BRENT (President, Gene Therapy) received a stock award from POSEIDA THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/1/2022ACC: 0001209191-22-014372
Officer· President, Gene Therapy
Since Feb 2022
+738.91K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
738.91K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+307.88K
Price / share
—
Trade value
—
% of position
New position
3/1/2022
0.00→307.88K
Total
Net shares
+307.88K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2022 | A · Award | +307.88K | — | — | New position | 0.00 | 307.88K |
| Total | +307.88K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
431.03K shares
Shares
+431.03K
Strike price
3.42
Held after
431.03K
Exercisable
—
3/1/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock431.03K shares | 3/1/2022 | A · Award | +431.03K | 3.42 | — | 431.03K |